Rapid improvement in Alzheimer’s disease symptoms following fecal microbiota transplantation: a case report
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD), the most common form of dementia, is a leading cause of death and a major cause of morbidity in older people. The disease is characterized by progressive memory loss, cognitive impairment, and the cerebral accumulation of amyloid-β peptide. Given the health and economic impacts of AD, treatments that target the underlying etiology of AD or modify the course of the disease are of significant interest. The gut microbiome has been increasingly implicated in the pathogenesis of several neurological diseases, including multiple sclerosis and Parkinson’s disease. Furthermore, emerging evidence has demonstrated that there are alterations in gut microbiome composition in patients with AD, suggesting involvement of the microbiome–gut–brain axis. We present symptom improvement in a patient with AD following fecal microbiota transplantation for a Clostridioides difficile infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In two case reports in humans, FMT improved gastrointestinal symptoms, cognition, and mood, along with the eradication of C. difficile in patients with Alzheimer’s disease (457, 458).”
From Signalling cognition: The gut microbiota and hypothalamic-pituitary-adrenal axis (2023) · cites this paper as [457]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“In these difficult-to-treat cases as well as in subsequent randomized, controlled trials, FMT has consistently achieved cure rates >90%.(11) Serendipitous improvements following FMT have since been reported in a number of extra-intestinal conditions, including ASD,(3) MS,(12,13) and myoclonus dystonia.”
BackgroundGut microbiome alterations in Alzheimer’s disease
Vogt, N. M., Kerby, R. L., Dill-McFarland, K. A., Harding, S. J., Merluzzi, A. P., Johnson, S. C., Carlsson, C. M., Asthana, S., Zetterberg, H., Blennow, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13601-y · Cited by 2,137
How common are the "common" neurologic disorders?
Hirtz, D., Thurman, D. J., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A. R., & Zalutsky, R. (2007) · Neurology · doi:10.1212/01.wnl.0000252807.38124.a3 · Cited by 1,365 · cited 1×
“most significant risk factor for the disease, with incidence doubling every 5 years after the age of 65.(1) Approximately 46.”
BackgroundHOW COMMON ARE THE “COMMON” NEUROLOGIC DISORDERS?
Kaplin, A. I., & Williams, M. (2007) · Neurology · doi:10.1212/01.wnl.0000278071.91524.4d · Cited by 1,131
Microglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911 · cited 1×
“Neuroinflammation plays a central role in the pathogenesis of AD,(22,23) and is characterized by elevated levels of proinflammatory cytokines,(23) nuclear factor jb signalling,(24) and aggregation of activated microglia in damaged areas.(25) The influence of the gut microbiome on neuroinflammation in AD remains poorly…”
BackgroundReduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota
Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Frisoni, G., Neher, J. J., Fåk, F., Jucker, M., Lasser, T., et al. (2017) · Scientific Reports · doi:10.1038/srep41802 · Cited by 901 · cited 1×
“This hypothesis has been supported by animal models;(8,9) for example, germ-free amyloidb precursor protein transgenic mice have markedly less cerebral amyloid-b pathology compared with control mice with intestinal bacteria.(8) Certain bacteria within the gut microbiota are also capable of secreting large amounts of a…”
BackgroundMiyake, S., Kim, S., Suda, W., Oshima, K., Nakamura, M., Matsuoka, T., Chihara, N., Tomita, A., Sato, W., Kim, S.-W., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137429 · Cited by 809 · cited 3×
“A growing body of experimental and clinical data implicates the gut microbiome in the pathogenesis of several neurological conditions, including autism spectrum disorder (ASD),(3) Parkinson’s disease (PD),(4) and multiple sclerosis (MS).(5,6) More recently, alterations in gut microbiome composition have been observed…”
BackgroundInfluentialLong-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota
Kang, D.-W., Adams, J. B., Coleman, D. M., Pollard, E. L., Maldonado, J., McDonough-Means, S., Caporaso, J. G., & Krajmalnik-Brown, R. (2019) · Scientific Reports · doi:10.1038/s41598-019-42183-0 · Cited by 749 · cited 1×
“In an open-label study in 18 children with ASD, 2 weeks of vancomycin treatment followed by daily FMT infusions for 7 to 8 weeks resulted in significant improvements in core ASD symptoms, which persisted at the 2-year follow-up.(3) Furthermore, in a case series of three patients with MS and underlying gastrointestinal…”
BackgroundMinter, M. R., Zhang, C., Leone, V., Ringus, D. L., Zhang, X., Oyler-Castrillo, P., Musch, M. W., Liao, F., Ward, J. F., Holtzman, D. M., et al. (2016) · Scientific Reports · doi:10.1038/srep30028 · Cited by 655
Understanding the mechanisms of faecal microbiota transplantation
Khoruts, A., & Sadowsky, M. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.98 · Cited by 561
Research works printed but not linked: 2
- Borody T, 2011, Am J Gastroenterol, 106, pS352
- Borody T, 2011, Am J Gastroenterol, 106, S352
Cited by
Chen, Y., Xu, J., & Chen, Y. (2021) · Nutrients · doi:10.3390/nu13062099 · Cited by 917
“from a healthy donor, providing a novel therapeutic strategy for AD treatment based on the modulation of gut microbiota [89].”
BackgroundSignalling cognition: The gut microbiota and hypothalamic-pituitary-adrenal axis
Rusch, J. A., Layden, B. T., & Dugas, L. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1130689 · Cited by 415
Communication of gut microbiota and brain via immune and neuroendocrine signaling
Kasarello, K., Cudnoch-Jedrzejewska, A., & Czarzasta, K. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1118529 · Cited by 247
“So far, few clinical trials have shown the beneficial effect of FMT on improving cognition, memory, and mood, as well as gut microbiota biodiversity and SCFA production in patients with AD (Hazan, 2020; Park et al., 2021).”
BackgroundThe role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
Current understanding of the Alzheimer’s disease-associated microbiome and therapeutic strategies
Seo, D.-O., & Holtzman, D. M. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01146-2 · Cited by 230
“Even 2 months after FMT, the patient showed rapid improvement in AD symptoms 88 .”
Background
Metadata
- Authors
- Hazan, S.
- Affiliations
- Ventura Clinical Trials, Malibu, CA, USA
- Corresponding author
- Hazan, Sabine
- ORCID
- Hazan, Sabine
- Venue
- Journal of International Medical Research
- Publisher
- SAGE Publications
- Published
- 2020-06
- Volume
- 48
- Issue
- 6
- Pages
- 300060520925930-300060520925930
- ISSN
- 0300-0605 (ISSN-L)
- 1473-2300
- PMC
- PMC7328362
- OpenAlex
- W3039498906
- Semantic Scholar
- 2e5fceca01a29a3f989d4c7262462c22a6f5b641
- Cited by
- 200
- References
- 28
- Citations by year
- 2026: 17 · 2025: 40 · 2024: 47 · 2023: 25 · 2022: 42 · 2021: 26 · 2020: 3
- FWCI
- 7.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of International Medical Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, fecal microbiota transplantation, gut microbiota, microbiome-gut-brain axis, Clostridium difficile infection, cognitive impairment, memory loss, amyloid-beta, dementia treatment
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Humans, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapid improvement in Alzheimer’s disease symptoms following fecal microbiota transplantation: a case report. https://app.cochat.ai/papers/10.1177/0300060520925930
- The paper
- Hazan, S. (2020). Rapid improvement in Alzheimer’s disease symptoms following fecal microbiota transplantation: a case report. Journal of International Medical Research. https://doi.org/10.1177/0300060520925930
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.